Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | LTA4H | P09960 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.46 |
| ▸ | HTR5A | P47898 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9469575 | 0.84 | POLB (0.63) | POLBSIGMAR1KMT2ALTA4H | |
| SCHEMBL2937792 | 0.84 | POLB (0.63) | POLBSIGMAR1KMT2ALTA4H | |
| SCHEMBL24322883 | 0.81 | POLB (0.51) | POLBKMT2ATDP1 | |
| SCHEMBL1162536 | 0.80 | POLB (0.56) | POLBKMT2ALTA4HMEN1TDP1 | |
| SCHEMBL1162602 | 0.80 | POLB (0.56) | POLBKMT2ALTA4HMEN1TDP1 | |
| SCHEMBL8854588 | 0.80 | POLB (0.56) | POLBKMT2ALTA4HMEN1TDP1 | |
| SCHEMBL478125 | 0.79 | POLB (0.69) | POLBKMT2ALTA4H | |
| SCHEMBL10425868 | 0.77 | SIGMAR1 (0.73) | SIGMAR1KMT2AMEN1TDP1DPP7 | |
| SCHEMBL13278472 | 0.77 | POLB (0.61) | POLBSIGMAR1KMT2ALTA4HGAA | |
| SCHEMBL11539185 | 0.76 | POLB (0.65) | POLBKMT2ALTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210053997-A1 | TRNA SYNTHETASE INHIBITORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2021-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210053997-A1 | TRNA SYNTHETASE INHIBITORS | TRMT1, AARS1, GARS1 | POLB 171/4885SIGMAR1 2321/4885KMT2A 1187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.